16 results about "Butyrolactone I" patented technology

This invention discloses a butyrolactone compound with multidrug resistance reverse transcription activity, its preparation method, and its uses. The compound's structural formula is shown in Figure I. The preparation method includes the following steps: fermenting *Aspergillus pyrolyticus* (accession number CCTCC NO: M2014086) to obtain a butyrolactone fermentation product; extracting the fermentation product with ethyl acetate to obtain a crude extract; degreasing the crude extract with hexane and dichloromethane to obtain a final extract; and purifying the final extract using normal-phase silica gel column chromatography, reversed-phase medium-pressure column chromatography, and reversed-phase semi-preparative high-performance liquid chromatography. The advantage of this butyrolactone compound is that it possesses multidrug resistance reverse transcription activity and the ability to regulate P-gp-mediated drug efflux in multidrug-resistant cell lines, making it a potential drug for treating multidrug-resistant cancers.

The invention belongs to the technical field of medicines, and particularly relates to an application of butyrolactone metabolic ketone I separated from a rat excrement metabolite of an aspergillus terreus secondary metabolite butyrolactone I in preparation of an antioxidant drug. The compound has an obvious anti-oxidation effect; the raw materials for preparing the compound are rich in resources, the extraction and separation technical difficulty is small, the solvent can be recycled, and the production cost is low.

The application discloses a kind of Baeyer-Villiger monooxygenase and its mutant in synthesis optical pure 3-substituted chiral butyrolactone Application, the application with the Baeyer-Villiger monooxygenase ArBVMO of Acinetobacter radioresistens (CGMCC No.25186) source of resistance to radiation Acinetobacter (Acinetobacter radioresistens) and its mutant as biocatalyst, can catalyze the asymmetric oxidation of series latent chiral 3-substituted cyclobutanone, preparation corresponding optical pure chiral butyrolactone.Compared with prior art, the application has the advantages of high enzyme reaction substrate concentration, mild reaction condition, environment-friendly, high space-time yield, high product optical purity, and has good application prospect.

The present application relates to a kind of biological gamma-butyrolactone and its production method, the production method of biological gamma-butyrolactone of the present application includes the following steps: preparation biological succinic acid solution;The obtained biological succinic acid solution and hydrogen continuously enter the fixed bed containing nickel copper catalyst and carry out hydrogenation reaction, obtain crude product;The obtained crude product enters separation column and is separated and purified, obtain biological gamma-butyrolactone;Nickel loading in the nickel copper catalyst is 30wt%~60wt%, copper loading is 1wt%~5wt%, the content of hydrophobic compound is 0.01wt%~0.2wt%.The present application is prepared by 5wt%~30wt% biological 1,4-butanedioic acid dilute solution continuously into fixed bed hydrogenation reactor, and biological gamma-butyrolactone liquid is prepared, continuously enters rectification separation column and is separated, and biological gamma-butyrolactone product with purity ≥99.99% can be prepared, and the rest is impurity;The impurity includes tetrahydrofuran and 1,4-butanediol;The content of tetrahydrofuran is ≤0.004%;The content of 1,4-butanediol is ≤0.005%.

The invention relates to a process for production and / or storage of α-methylenelactones, wherein a α- methylenelactone is present in a vessel, the α-methylenelactone is a α-methylenelactone of the following Formula I: and R1 is hydrogen, or a C1 to C10, in particular C1 to C5, linear or branched alkyl group, in particular R1 is hydrogen or a methyl group, and the vessel contains a gaseous phase and a liquid phase, wherein the gaseous phase comprises less than 15 vol.-%, based on the total gaseous phase, of oxygen, and the liquid phase comprises - 50.0000 wt.-% to 99.9995 wt.-%, based on the total liquid phase, of the α-methylenelactone, - 0.0000 wt.-% to 49.9995 wt.-%, based on the total liquid phase, of residuals, in particular carboxylic acids such as itaconic acid, hydroxycarboxylic acids such as 2-methylene-4-ol-butyric acid, hydroxycarboxylic esters such as γ-butyrolactone, water, further monomers, and / or organic solvents, and - 0.0005 wt.-% to 0.2000 wt.-%, based on the total liquid phase, of a polymerization inhibitor, wherein the polymerization inhibitor is an aminoxyl radical of the following Formular II: and R2 is hydrogen, oxygen, OH NH2, OMe or an alkyl-, ester- or amide group, wherein the polymerization inhibitor is in particular 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl.

The present invention relates to a carbonyl reductase mutant and its application in the stereoselective synthesis of aromatic multi-substituted chiral γ-butyrolactone. The carbonyl reductase mutant is a protein derived from carbonyl reductase SsCR, whose amino acid sequence is substituted, deleted or added with several amino acids as shown in SEQ ID No.2 and can catalyze the asymmetric reduction of aromatic α- / β-unsaturated ketoesters, and whose catalytic activity is higher than that of carbonyl reductase SsCR, wherein the amino acid sequence of carbonyl reductase SsCR is shown in SEQ ID No.2. The present invention also provides a gene encoding the carbonyl reductase mutant, a recombinant expression vector and a recombinant expression transformant containing the gene, and the application of the carbonyl reductase mutant in the synthesis of chiral aromatic multi-substituted γ-butyrolactone. Compared with the prior art, the present invention has the significant advantages of simple process, high atom economy, high product optical purity and environmental friendliness, and has good industrial application prospects.

The invention provides a method for synthesizing alpha-bromo-gamma-butyrolactone, which comprises the following step: by using 1-propyl phosphoric anhydride or 1-butyl phosphoric anhydride as a catalyst, reacting a substrate gamma-butyrolactone with a bromination reagent to obtain the alpha-bromo-gamma-butyrolactone. According to the method, the used raw material gamma-butyrolactone is cheap and easy to obtain, the route is short, the operation is convenient, the finally obtained by-products are few and easy to treat and purify, and the product with higher purity can be obtained without rectification.

The application belongs to the technical field of medicine synthesis, and particularly relates to an alpha-methenyl-gamma-butyrolactone compound and an asymmetric kinetic resolution synthesis method thereof. The compound provided by the application is shown as formula I. The application provides a simple, efficient and alpha-methenyl-gamma-butyrolactone compound synthesis method. The series of compounds prepared have good antitumor activity and good application prospect.

The present application relates to an ene reductase mutant and its application in the synthesis of chiral aromatic polysubstituted gamma-butyrolactone. The ene reductase mutant is a protein formed by replacing the tryptophan at position 100 of the amino acid sequence shown in SEQ ID No. 2 with alanine. The present application provides a new ene reductase mutant SsER-A314Y / W100A, and a double enzyme cascade catalytic system is constructed with the mutant SsCR-V3 (V126A / N210H / M215G) of the carbonyl reductase SsCR for the efficient stereoselective synthesis of various aromatic chiral gamma-butyrolactone. Compared with the prior art, the aromatic chiral gamma-butyrolactone double enzyme cascade system provided by the present application has the significant advantages of simple process, high atom economy, high optical purity of product and environmental friendliness, and has good industrial application prospect.

The invention discloses a catalytic asymmetric synthesis method of a beta-substituted gamma-butyrolactone compound, which comprises the following steps: under the action of palladium acetate, a chiral ligand, an acidic additive, an oxidant and a pro-oxidant, reacting an allyl alcohol compound with an alkenyl ether compound in an organic solvent to obtain the beta-substituted gamma-butyrolactone compound, the invention also provides podophyllotoxin, a homologue thereof and a synthesis method of a chiral intermediate compound in a synthesis process of the podophyllotoxin. According to the method, one-pot reaction / oxidation reaction is adopted, so that catalytic asymmetric synthesis of the beta-substituted-gamma-butyrolactone compound is economically and efficiently realized; the reaction substrates are two chemical raw materials and are good in universality, reaction conditions are mild, the process is simple and safe, and operation is easy and convenient.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a product for preventing and / or treating hyperuricemia and / or uric acid nephropathy. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the capacity of remarkably improving hyperuricemia and uric acid nephropathy, and the blood uric acid level, the serum creatinine level and the blood urea nitrogen level of hyperuricemia mice induced by oteracil potassium and hypoxanthine and uricase knockout mice are remarkably improved; the compound can be applied to preparation of products for preventing and / or treating the hyperuricemia and / or the uric acid nephropathy, a new product is provided for prevention and treatment of the hyperuricemia and the uric acid nephropathy, and therefore the compound has a wide application prospect.

The invention discloses a catalyst for preparing gamma-butyrolactone through dimethyl maleate hydrogenation as well as a preparation method and application of the catalyst. The catalyst is of a core-shell structure, the core is Cu-A-O, the shell is MO-B, A is an auxiliary agent and is selected from one or more of Zn, Mn, Ba, Mg, Ti, Ge, Zr and Cr; m is an active metal component and is selected from one or more of Pd, Ni, Pt, Au and Ag; and B is a carrier component. The catalyst is used in the process of preparing gamma-butyrolactone through dimethyl maleate hydrogenation, the conversion rate and gamma-butyrolactone selectivity can be improved, catalyst coking can be avoided, and the operation life of the catalyst is prolonged.

The application belongs to the technical field of medicine, and discloses application of butyrolactone I in preparation of a medicine for treating chronic kidney disease, wherein the butyrolactone I has the structure shown in formula 1. The application provides a brand-new use of the known compound butyrolactone I. By evaluating the progress of treating chronic kidney disease of the compound butyrolactone I, it is found that the compound can effectively inhibit the progress of chronic kidney disease of mice, improve kidney function, inhibit oxidative stress damage, reduce secretion of inflammatory factors and the like in a mouse chronic kidney disease model, thereby reducing kidney fibrosis, blocking the progress of acute kidney injury to chronic kidney disease, and the compound can be used as a lead compound for developing a medicine for treating chronic kidney disease.

A method for preparing gamma-butyrolactone including converting furoic acid to the gamma-butyrolactone in an undivided cell without a mediator for paired electrolysis, including the steps of: a) electrochemically oxidizing the furoic acid to 2(5H)-furanone; and b) electrochemically reducing the 2(5H)-furanone to the gamma-butyrolactone.

Applications of butyrolactone-I in preparation of medicine for preventing aluminum-induced neuroinflammation and / or memory and cognitive disorder in zebrafish are provided. The applications have proven that at the animal level, butyrolactone-I may prevent aluminum-induced neuroinflammation and improve memory and cognitive disorder through the targets of antioxidation-inhibition of acetylcholinesterase activity-antiinflammation-regulation of intestinal flora disorder, and that butyrolactone-I may be used to prepare medicine for preventing aluminum-induced neuroinflammation and / or improving memory and cognitive disorder, thus providing a feasible scheme for preventing neurodegenerative diseases in clinical medicine.

The application discloses synthesis of a sparteine derivative ligand and application of the sparteine derivative ligand in preparation of chiral beta-butyrolactone, and specifically, the sparteine derivative ligand is prepared from sparteine, a catalyst is prepared in situ from the sparteine derivative ligand and a metal iridium precursor, and the catalyst is used for catalyzing asymmetric hydrogenation of a double ethylene ketone to synthesize chiral beta-butyrolactone. The synthesis route of the ligand is simple, the catalyst has high activity and low cost, and the chemical selectivity and the stereoselectivity are very high, so that the production cost of the beta-butyrolactone is greatly reduced.